AZ and Merck's Lynparza meets in Phase II for metastatic CRPC

AstraZeneca plc (LSE:AZN; NYE:AZN) and Merck & Co. Inc. (NYSE:MRK) said Lynparza olaparib in combination with Zytiga abiraterone met the primary endpoint of improving radiologic progression-free survival (PFS) in

Read the full 292 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE